Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.
复制标题
钙通道阻滞剂苯磺酸钠治疗与COVID-19高血压患者的病死率降低相关。
DOI：
10.1038/s41421-020-00235-0
复制
发表时间：
2020-12-22
期刊：
影响因子：
33.5
通讯作者：
Xiao G
中科院分区：
文献类型：
--
作者：
Zhang LK;Sun Y;Zeng H;Wang Q;Jiang X;Shang WJ;Wu Y;Li S;Zhang YL;Hao ZN;Chen H;Jin R;Liu W;Li H;Peng K;Xiao G
由新型严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的冠状病毒病(新冠肺炎)现已蔓延至200个国家，构成全球公共卫生问题。患有高血压等共病的患者感染更严重，死亡率更高。治疗新冠肺炎患者迫切需要开发有效的抗病毒药物。本文报道了临床上广泛使用的抗高血压药物钙通道阻滞剂(CCBS)在体外可抑制SARS-CoV-2进入后的复制事件，而另外两种主要的抗高血压药物，即血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂，在体外无抗SARS-CoV-2的作用。CCB与氯喹联合应用可显著增强抗SARS-CoV-2的效果。对住院的新冠肺炎合并高血压患者的临床回顾调查显示，苯磺酸氨氯地平治疗可降低病死率。本研究结果提示，对新冠肺炎合并高血压患者给予建行降压治疗，可改善疾病转归。
The coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to >200 countries posing a global public health concern. Patients with comorbidity, such as hypertension suffer more severe infection with elevated mortality. The development of effective antiviral drugs is in urgent need to treat COVID-19 patients. Here, we report that calcium channel blockers (CCBs), a type of antihypertensive drug that is widely used in clinics, inhibited the post-entry replication events of SARS-CoV-2 in vitro, while no in vitro anti-SARS-CoV-2 effect was observed for the two other major types of antihypertensive drugs, namely, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. CCB combined with chloroquine showed a significantly enhanced anti-SARS-CoV-2 efficacy. A retrospective clinical investigation on hospitalized COVID-19 patients with hypertension as the only comorbidity revealed that the CCB amlodipine besylate therapy was associated with a decreased case fatality rate. The results from this study suggest that CCB administration to COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.
登录
查看更多内容
影响因子：
4
作者：
Missiaen, L;Callewaert, G;Parys, JB
通讯作者：
Parys, JB
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
7.2
作者：
Marfella, R.;Paolisso, P.;Paolisso, G.
通讯作者：
Paolisso, G.
影响因子：
17.1
作者：
Lavanya M;Cuevas CD;Thomas M;Cherry S;Ross SR
通讯作者：
Ross SR
影响因子：
5.6
作者：
D'Elia JA;Weinrauch LA
通讯作者：
Weinrauch LA